Annual CFO
-$36.50 M
-$5.59 M-18.09%
01 June 2022
Summary:
Pluristem Therapeutics annual cash flow from operations is currently -$36.50 million, with the most recent change of -$5.59 million (-18.09%) on 01 June 2022. During the last 3 years, it has fallen by -$5.59 million (-18.09%).PSTI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$7.61 M
+$818.00 K+9.71%
01 September 2022
Summary:
Pluristem Therapeutics quarterly cash flow from operations is currently -$7.61 million, with the most recent change of +$818.00 thousand (+9.71%) on 01 September 2022.PSTI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$35.32 M
+$1.18 M+3.23%
01 September 2022
Summary:
Pluristem Therapeutics TTM cash flow from operations is currently -$35.32 million, with the most recent change of +$1.18 million (+3.23%) on 01 September 2022.PSTI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTI Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -18.1% | +13.4% | -5.3% |
| 5 y5 years | -23.9% | -5.1% | -25.3% |
PSTI Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | >+9999.0% | -175.3% | -449.7% |
Pluristem Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$7.61 M(-9.7%) | -$35.32 M(-3.2%) |
| June 2022 | -$36.50 M(+18.1%) | -$8.43 M(-10.6%) | -$36.50 M(-3.1%) |
| Mar 2022 | - | -$9.42 M(-4.5%) | -$37.67 M(+5.9%) |
| Dec 2021 | - | -$9.86 M(+12.2%) | -$35.58 M(+6.0%) |
| Sept 2021 | - | -$8.79 M(-8.4%) | -$33.56 M(+8.6%) |
| June 2021 | -$30.91 M(+17.2%) | -$9.60 M(+30.9%) | -$30.91 M(+11.9%) |
| Mar 2021 | - | -$7.33 M(-6.6%) | -$27.64 M(+3.1%) |
| Dec 2020 | - | -$7.84 M(+27.7%) | -$26.81 M(+6.1%) |
| Sept 2020 | - | -$6.14 M(-2.9%) | -$25.27 M(-4.2%) |
| June 2020 | -$26.37 M(-10.5%) | -$6.32 M(-2.8%) | -$26.37 M(-1.3%) |
| Mar 2020 | - | -$6.50 M(+3.2%) | -$26.72 M(+1.9%) |
| Dec 2019 | - | -$6.30 M(-13.0%) | -$26.22 M(-7.0%) |
| Sept 2019 | - | -$7.24 M(+8.5%) | -$28.18 M(-4.3%) |
| June 2019 | -$29.45 M(+37.8%) | -$6.67 M(+11.1%) | -$29.45 M(+3.1%) |
| Mar 2019 | - | -$6.01 M(-27.3%) | -$28.57 M(+1.5%) |
| Dec 2018 | - | -$8.26 M(-2.9%) | -$28.14 M(+13.9%) |
| Sept 2018 | - | -$8.51 M(+47.1%) | -$24.70 M(+15.5%) |
| June 2018 | -$21.38 M(-1.1%) | -$5.79 M(+3.8%) | -$21.38 M(-2.7%) |
| Mar 2018 | - | -$5.58 M(+15.5%) | -$21.98 M(+0.2%) |
| Dec 2017 | - | -$4.83 M(-7.0%) | -$21.93 M(-4.1%) |
| Sept 2017 | - | -$5.19 M(-18.8%) | -$22.88 M(+5.9%) |
| June 2017 | -$21.61 M(+16.7%) | -$6.39 M(+15.7%) | -$21.61 M(+4.1%) |
| Mar 2017 | - | -$5.52 M(-4.4%) | -$20.77 M(-0.3%) |
| Dec 2016 | - | -$5.78 M(+47.2%) | -$20.83 M(+11.5%) |
| Sept 2016 | - | -$3.92 M(-29.2%) | -$18.68 M(+0.8%) |
| June 2016 | -$18.52 M(-10.1%) | -$5.54 M(-0.8%) | -$18.52 M(+2.9%) |
| Mar 2016 | - | -$5.59 M(+54.3%) | -$18.00 M(-5.1%) |
| Dec 2015 | - | -$3.62 M(-3.9%) | -$18.97 M(-9.3%) |
| Sept 2015 | - | -$3.77 M(-24.9%) | -$20.92 M(+1.5%) |
| June 2015 | -$20.61 M(+7.8%) | -$5.02 M(-23.5%) | -$20.61 M(-1.6%) |
| Mar 2015 | - | -$6.56 M(+17.8%) | -$20.94 M(+4.5%) |
| Dec 2014 | - | -$5.57 M(+61.2%) | -$20.04 M(+14.6%) |
| Sept 2014 | - | -$3.46 M(-35.5%) | -$17.48 M(-8.6%) |
| June 2014 | -$19.12 M(+13.2%) | -$5.36 M(-5.3%) | -$19.12 M(+1.8%) |
| Mar 2014 | - | -$5.66 M(+87.8%) | -$18.78 M(+3.7%) |
| Dec 2013 | - | -$3.01 M(-40.9%) | -$18.10 M(-1.9%) |
| Sept 2013 | - | -$5.09 M(+1.6%) | -$18.46 M(+9.3%) |
| June 2013 | -$16.89 M(+415.6%) | -$5.01 M(+0.6%) | -$16.89 M(+31.9%) |
| Mar 2013 | - | -$4.98 M(+48.0%) | -$12.80 M(+23.8%) |
| Dec 2012 | - | -$3.37 M(-4.4%) | -$10.34 M(+0.8%) |
| Sept 2012 | - | -$3.52 M(+278.7%) | -$10.26 M(+213.2%) |
| June 2012 | -$3.27 M | -$930.00 K(-63.1%) | -$3.27 M(-27.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | -$2.52 M(-23.4%) | -$4.50 M(+34.0%) |
| Dec 2011 | - | -$3.29 M(-195.0%) | -$3.36 M(+109.3%) |
| Sept 2011 | - | $3.46 M(-260.3%) | -$1.61 M(-72.1%) |
| June 2011 | -$5.75 M(+6.4%) | -$2.16 M(+56.8%) | -$5.75 M(+9.4%) |
| Mar 2011 | - | -$1.38 M(-10.1%) | -$5.26 M(-8.1%) |
| Dec 2010 | - | -$1.53 M(+122.5%) | -$5.72 M(+11.1%) |
| Sept 2010 | - | -$688.00 K(-58.7%) | -$5.16 M(-4.7%) |
| June 2010 | -$5.41 M(+26.9%) | -$1.66 M(-9.7%) | -$5.41 M(+13.2%) |
| Mar 2010 | - | -$1.84 M(+91.7%) | -$4.78 M(+17.1%) |
| Dec 2009 | - | -$961.00 K(+2.1%) | -$4.08 M(+20.0%) |
| Sept 2009 | - | -$941.00 K(-8.8%) | -$3.40 M(-20.3%) |
| June 2009 | -$4.26 M(-6.1%) | -$1.03 M(-9.9%) | -$4.26 M(-13.0%) |
| Mar 2009 | - | -$1.15 M(+308.9%) | -$4.90 M(+10.3%) |
| Dec 2008 | - | -$280.00 K(-84.5%) | -$4.44 M(-12.2%) |
| Sept 2008 | - | -$1.80 M(+8.1%) | -$5.06 M(+11.5%) |
| June 2008 | -$4.54 M(+47.7%) | -$1.67 M(+143.1%) | -$4.54 M(+7.6%) |
| Mar 2008 | - | -$687.00 K(-23.4%) | -$4.22 M(-1.4%) |
| Dec 2007 | - | -$897.00 K(-30.1%) | -$4.28 M(+17.0%) |
| Sept 2007 | - | -$1.28 M(-4.9%) | -$3.66 M(+19.1%) |
| June 2007 | -$3.07 M(+50.0%) | -$1.35 M(+80.0%) | -$3.07 M(+32.0%) |
| Mar 2007 | - | -$749.00 K(+170.4%) | -$2.33 M(+6.6%) |
| Dec 2006 | - | -$277.00 K(-60.3%) | -$2.18 M(-6.1%) |
| Sept 2006 | - | -$697.00 K(+15.6%) | -$2.32 M(+13.5%) |
| June 2006 | -$2.05 M(+14.3%) | -$603.20 K(-0.3%) | -$2.05 M(+6.3%) |
| Mar 2006 | - | -$605.10 K(+44.8%) | -$1.93 M(-2.7%) |
| Dec 2005 | - | -$418.00 K(-0.7%) | -$1.98 M(+12.3%) |
| Sept 2005 | - | -$420.80 K(-12.6%) | -$1.76 M(-1.6%) |
| June 2005 | -$1.79 M(+18.5%) | -$481.20 K(-27.0%) | -$1.79 M(+3.8%) |
| Mar 2005 | - | -$659.50 K(+226.6%) | -$1.73 M(+17.2%) |
| Dec 2004 | - | -$201.90 K(-55.0%) | -$1.47 M(-11.1%) |
| Sept 2004 | - | -$449.10 K(+8.1%) | -$1.66 M(+9.6%) |
| June 2004 | -$1.51 M(+289.3%) | -$415.60 K(+2.4%) | -$1.51 M(+8.9%) |
| Mar 2004 | - | -$405.90 K(+5.1%) | -$1.39 M(+32.4%) |
| Dec 2003 | - | -$386.10 K(+26.9%) | -$1.05 M(+55.1%) |
| Sept 2003 | - | -$304.20 K(+4.1%) | -$676.60 K(+74.2%) |
| June 2003 | -$388.30 K(+504.8%) | -$292.30 K(+339.5%) | -$388.30 K(+270.2%) |
| Mar 2003 | - | -$66.50 K(+389.0%) | -$104.90 K(+72.2%) |
| Dec 2002 | - | -$13.60 K(-14.5%) | -$60.90 K(-100.6%) |
| Sept 2002 | - | -$15.90 K(+78.7%) | $10.05 M(-0.2%) |
| June 2002 | -$64.20 K | -$8900.00(-60.4%) | $10.07 M(-0.1%) |
| Mar 2002 | - | -$22.50 K(-100.2%) | $10.08 M(-0.2%) |
| Dec 2001 | - | $10.10 M | $10.10 M |
FAQ
- What is Pluristem Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Pluristem Therapeutics?
- What is Pluristem Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Pluristem Therapeutics?
- What is Pluristem Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Pluristem Therapeutics?
What is Pluristem Therapeutics annual cash flow from operations?
The current annual CFO of PSTI is -$36.50 M
What is the all time high annual CFO for Pluristem Therapeutics?
Pluristem Therapeutics all-time high annual cash flow from operations is -$64.20 K
What is Pluristem Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PSTI is -$7.61 M
What is the all time high quarterly CFO for Pluristem Therapeutics?
Pluristem Therapeutics all-time high quarterly cash flow from operations is $10.10 M
What is Pluristem Therapeutics TTM cash flow from operations?
The current TTM CFO of PSTI is -$35.32 M
What is the all time high TTM CFO for Pluristem Therapeutics?
Pluristem Therapeutics all-time high TTM cash flow from operations is $10.10 M